Brief: Oramed Announces Positive Safety And Efficacy Data From Its Phase 2 Clinical Trial Of Ormd-0801

Oramed Pharmaceuticals

17/11/2022 22:26

Nov 17 (Reuters) - Oramed Pharmaceuticals Inc  ORMP.O :
    * ORAMED ANNOUNCES ADDITIONAL POSITIVE SAFETY AND EFFICACY
DATA
FROM ITS PHASE 2 CLINICAL TRIAL OF ORMD-0801 FOR NASH
    * ORAMED PHARMACEUTICALS INC - ACHIEVED PRIMARY ENDPOINT OF
SAFETY
AND TOLERABILITY IN PARTICIPANTS WITH TYPE 2 DIABETES WITH NASH
    * ORAMED - ORAL INSULIN CANDIDATE SHOWS CONSISTENT TRENDS
ACROSS
KEY SECONDARY ENDPOINTS WITH REDUCTION OF LIVER FAT, LIVER
STIFFNESS AND LIPIDS
    * ORAMED PHARMACEUTICALS INC - PRIMARY OBJECTIVE OF SAFETY
MET
WITH NO SERIOUS ADVERSE EVENTS
    * ORAMED PHARMACEUTICALS INC - NO DIFFERENCE IN INCIDENCE
RATE OF
ADVERSE EVENTS BETWEEN ORMD-0801 AND PLACEBO

Source text for Eikon:  ID:nPn621Gbwa 
Further company coverage:  ORMP.O 
 ((Reuters.Briefs@thomsonreuters.com;))